Table 5 Summary of included studies for HNF1A- and HNF4A-diabetes
From: Precision treatment of beta-cell monogenic diabetes: a systematic review
Study ID | Number of participants (HNF1A/HNF4A) | Sex (M/F) | Baseline group treatment | Comparison | Mean or median Pre-HbA1c (%) | Mean or median Post-HbA1c (%) | Mean, median, or minimal interval between pre/post HbA1c (months) | |
|---|---|---|---|---|---|---|---|---|
HNF1A-diabetes & HNF4A-diabetes Cohort studies or case series | ||||||||
Carlsson et al.21 | 17 (10/7) | 3/7 (HNF1A) 1/6 (HNF4A) | 5 None 10 Insulin 1 Insulin + MET 1 MET | 5 None 3 Insulin 7 SU, SU + insulin 1 SU + DPP4i | 8.3 | 7.0 | 83 | |
13 (11/2) (Median diabetes duration: 4.6) | 9/4 | 12 Insulin 0 Insulin + MET 1 MET | 1 Diet 12 SU | 7.5 | 6.4 | 24 | ||
23 (18/5) Median diabetes duration: 18.1 | 19/4 | 17 Insulin 2 Insulin + MET 4 MET | 2 Diet 6 SU, 6 SU + MET, 3 SU + insulin, 3 SU + insulin + additional agent, 3 Insulin ± non-SU additional agent | 8.8 | 9.2 | 24 | ||
HNF1A-diabetes Cohort studies or case series | ||||||||
Kyithar et al.44 | 4 2 | NR NR | None Insulin | SU SU | 7.5 7.4 | 6.8 6.5 | 16 19 | |
HNF1A-diabetes uncontrolled experimental study | ||||||||
Shepherd et al.29 | 8 | NR | Insulin | SU | Median reduction in HbA1c (%)0.8 (−2.5–3.2) | 6 | ||
HNF1A-diabetes Cross-sectional studies (uncontrolled group comparisons) | ||||||||
Raile et al.45 | 114a | 41/73 | Mean HbA1c (%) | |||||
Insulin (n = 34) | SU (n = 16) | Insulin + SU (n = 14) | Glinides (n = 13) | Glinides + Insulin (n = 9) | None (n = 28) | |||
7.5 [6.2, 8.3] | 6.7 [5.8, 7.4] | 7.9 [6.7, 8.9] | 6.8 [5.9, 7.2] | 7.2 [6.6, 7.9] | 6.1 [5.1, 6.6] | |||
